



T.C.

ISTANBUL MEDİPOL UNIVERSITY

HEALTH SCIENCES INSTITUTE

MASTER THESIS

**EVALUATION OF DIGOXIN AS ANTI-CANCER AGENT IN  
COLON CANCER CELL LINE**

KALIF MOHAMED MOHAMUD

DEPARTMENT OF BIOCHEMISTRY

SUPERVISOR

Assist. Prof. S. Sibel Erdem

ISTANBUL - 2017

## THESIS APPROVAL FORM

Institute : İstanbul Medipol University Institute of Health Sciences  
Level of Programme : Master (X) Doctorate ( )  
Department : Biochemistry  
Student : KALIF MOHAMED MOHAMUD  
Title : Evaluation Of Digoxin As Anti-Cancer Agent In Colon  
Cancer Cell Line  
Place : İstanbul Medipol University  
Examination date : 08.08.2017

We have reviewed the present thesis in regard to content and quality and approved as a Master Thesis.

### Supervisor

Assist.Prof S.Sibel ERDEM

### Institution

İstanbul Medipol University

### Signature



### Members of Examination Jury

Professor Nesrin EMEKLI

İstanbul Medipol University

Professor Ahmet Ata ALTURFAN

İstanbul University



Based on above jury's decision this MSc thesis the board of the Health Science Institute dated on 15.08/2017. and cited 2017/..24... - .39.... has approved to this thesis according the thesis Writing Guidance Regulations.

**Professor Nesrin EMEKLI**

Director of Institute of Health Sciences



## DECLARATION

I hereby declare that this thesis is my own study, in all steps of the thesis from planning to writing, I have not done anything out of the ethical behaviors, I have obtained all of the information of this thesis inside the academic and ethical principles, I have shown references to all of the information and comments that were reached other out of this thesis study and have shown these references at the section of references, also I have not done any behavior infringing patent and copyright during the performing and writing of this thesis.

Kalif Mohamed Mahamud



## **AKNOWLEDGEMENTS**

First and foremost thanks to the Allah who has granted me all these graces to complete this Project and plessed me by his power, mercy, and patience during my life.

It is a pleasure to find the chance to thank all the people that were directy or indirect involved in the success of completion of this master thesis.

First of all I would like to thank my Supervisor Assistant Professor S. Sibel Erdem for her kindly help, her continuous support, and encouragement throughout the completion of this work. Without her guidance, advice, motivation, and her rich source of ideas this thesis would not be what it is today.

I would like to thank Professor Nesrin Emekli and Associate Professor Türkan Yigitbaşı for their enormous amount of support, advice, and encouragement during my master's study really they are important factors for my successful and jury member Professor Ahmet Ata Alturfan.

I would like to thank Ms. Vildan for her support, and helping during my experiment.

I am very grateful to my mother, to my wife and children, to my brothers and sisters for their supporting and encouragement.

I would like to thank all my friends specially Ahmed, Mohamed, and Abdishakur for their support and motivation.

Finally I would like to thank İHH and Zamzam foundation for providing scholarship and financial support.

# CONTENTS

Page number

<b>THESIS APPROVAL FORM.....</b>	<b>I</b>
<b>DECLARATION.....</b>	<b>II</b>
<b>ACKNOWLEDGEMENTS.....</b>	<b>III</b>
<b>CONTENTS.....</b>	<b>IV-VI</b>
<b>ABBREVIATIONS AND SYMBOLS.....</b>	<b>VII</b>
<b>LIST OF TABLE.....</b>	<b>VIII</b>
<b>LIST OF FIGURES .....</b>	<b>VIII</b>
<b>1. ABSTRACT.....</b>	<b>1</b>
<b>2. ÖZET.....</b>	<b>2</b>
<b>3. INTRODUCTION.....</b>	<b>3</b>
3.1. Introduction.....	3
3.1.1 Objectives.....	5
3.1.2 Problem statement.....	5
3.1.3 Purpose of the study.....	5
3.1.4 Hypotheses.....	6
<b>4. GENERAL INFORMATION.....</b>	<b>7</b>
4.1. What is cancer?.....	7
4.2. Morphological and biochemical changes.....	9
4.2.1 Morphological changes.....	9
4.2.2 Biochemical changes.....	9
4.3. Types of cancer.....	10
4.3.1 Carcinomas.....	10

4.3.2 Sarcoma.....	10
4.3.3 Lymphoma.....	10
4.3.4 Leukemia.....	11
4.4. Cancer cell metabolism.....	11
4.4.1 Metabolic alterations associated with cancer.....	12
4.4.2.Regulation of cancer cell metabolism.....	12
4.4.3 Hypoxia and cancer cell metabolism.....	13
4.4.4 Metabolic signaling in cancer cells.....	14
4.4.5 Metabolic behavior of cancer cells.....	14
4.5. Colorectal cancer (CRC) .....	15
4.6 Apoptosis.....	15
4.6.1 Features of apoptosis.....	16
4.6.2 Significance of apoptosis.....	16
4.6.3 Correlation between apoptosis and proliferation.....	16
4.7 Treatment of cancer.....	17
4.7.1 What is Irinotecan?.....	17
4.7.1.1 How Irinotecan Works.....	19
4.7.1.2 Side effects.....	19
4.7.2 Digoxin.....	20
4.7.2.1 Anti-cancer and Anti-proliferative effects properties of digoxin.....	22

4.7.2.2 Cardiac glycosides in cancer treatment.....	23
4.7.2.3 Digoxin toxicity.....	23
4.7.2.4 Side effects of digoxin.....	23
4.7.2.5 Metabolism and excretionof digoxin.....	24
4.7.3 Combination therapy.....	24
<b>5. MATERIALS AND METHOD.....</b>	<b>29</b>
5.1 Material.....	29
5.2 Method.....	29
5.2.1 Cell Culture Experiments.....	29
5.2.2 Digoxin Cytotoxicity.....	29
5.2.3 Irinotecan Cytotoxicity.....	30
5.2.4 IC50 Determination and Analysis.....	30
5.2.5 Combination Therapy.....	31
5.2.6 CompuSyn Analysis.....	31
<b>6. RESULTS .....</b>	<b>32</b>
<b>7. DISCUSSION.....</b>	<b>39</b>
<b>8. REFERENCES.....</b>	<b>46</b>
<b>9. CURRICULUM VITAE.....</b>	<b>58</b>

## ABBREVIATIONS

AFP	Alpha fetoprotein
ATP	Adenosine triphosphate
CEA	Carcinoembryonic antigen
CI	Combination index
CRC	Colorectal cancer
DNA	Deoxyribonucleic acid
DMEM	Dulbecco's modified Eagle's medium
DMSO	Dimethyl sulfoxide
DRI	Dose reduction index
F <sub>a</sub>	Fraction affected
HIF	Hypoxia inducible factor
HL	Hodgkin lymphoma
IC50	Half maximal inhibitory concentration
MMS	Mitochondrial metabolic signaling
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NADPH	Nicotinamide adenine dinucleotide phosphate
NHL	Non-Hodgkin lymphoma
PBS	Phosphate-buffered saline
PPP	Pentose phosphate pathway
UV	Ultraviolet



## LIST OF TABLES

<b>Table: 4.7.3</b> Properties of Digitalis Glycosides.....	21
<b>Table: 6.4</b> Theoretical and experimental comparison for combinational affect declarement.....	36
<b>Table: 6.5</b> Dose Reduction Index Values of Digoxin and Ironetcan in Combination Therapy.....	38

## LIST OF FIGURES

<b>Figure: 4.7.1</b> Structure of Irinotecan.....	18
<b>Figure: 4.7.2</b> Structure of Digoxin.....	20
<b>Figure: 4.7.4</b> Action mechanism of biochemical .....	22
<b>Figure: 5.2.5</b> Concentration of digoxin and Irinotecan.....	31
<b>Figure: 6 .a.</b> Digoxin treatment with 24 hrs incubation.....	32
<b>Figure: 6. b.</b> Irinotecan treatment with 24hrs incubation.....	32
<b>Figure:6.1</b> HCT 116 colon cancer under the light microscope.....	33
<b>Figure:6.2</b> Cell viabilty after combination therapy of Digoxin and Irinotecan.....	33
<b>Figure; 6.3</b> Combination index graph for Digoxin and Irinotecan.....	34

## 1. ABSTRACT

### EVALUATION OF DIGOXIN AS ANTI-CANCERAGENT IN COLON CANCER CELL LINE

Colorectal cancer is a common disease all over the world and the occurrence of colorectal cancer is increasing in developing countries. Generally the occurrence and mortality of colorectal cancer are substantially advanced in men than women. Many factors play a significant role in the advancement of cancer. Genetics, diet, alcohol, smoking, and other environmental factors are among the main causes for colorectal cancer growth.

The major goal of this study was to develop an *in vitro* cell culture based assay to investigate the effect of combination therapy of Digoxin and Irinotecan on chosen Human Colon Cancer Type (HCT 116) colon cancer cell line. Another objective was to examine the anticancer effect of Digoxin on HCT 116 cell line regarding to cell proliferation, apoptosis and inflammation.

Digoxin, which is a commonly used cardiac glycoside, and chemotherapy agent called Irinotecan are chosen for the study. Initially, the colon carcinoma cell line HCT 116 was treated with varying concentrations of Digoxin to study its effect on cell survival and proliferation. Treatment of Digoxin not only inhibited the growth of HCT 116 cell line but also Digoxin induced apoptosis and disrupted cell membrane. IC50 values for Digoxin and Irinotecan were determined as 78  $\mu\text{M}$  and 330  $\mu\text{M}$ , respectively. When Digoxin is used in combination with Irinotecan, the findings clearly showed that two drugs had synergistic effects at all concentrations at certain ratios. The results showed that 55% of the cell death could be achieved if the Irinotecan is used at 94.99  $\mu\text{M}$  in combination with 68.8  $\mu\text{M}$  Digoxin.

Our results showed that the system composed of Digoxin and Irinotecan has positive outcome on the treatment of colon cancer. The results indicated that these two drugs can be used to generate more effective treatment for colorectal cancer as well as for other cancer types in near future.

**Key words:** Digoxin, Irinotecan, Anti-cancer Agent, Colon Cancer

## 2. ÖZET

### KOLON KANSERİ HÜCRE KÜLTÜRÜNDE DİGOXİN'İN ANTI KANSER ÖZELLİĞİNİN ARAŞTIRILMASI

Kolorektal kanser dünyada sık karşılaşılan hastalıklardan biri olup, insidansı gelişen ülkelerde artmaktadır. Genel olarak kolorektal kanserden ölüm oranları erkeklerde kadınlardan çok daha sık görülmektedir. Kanserin gelişmesinde etkin pek çok faktör bulunmaktadır. Kolorektal kanser gelişiminde genetik yapı, diyet, alkol, tütün ürünleri ve benzeri çevresel faktörler önem teşkil etmektedir.

Bu çalışmanın ana hedefi Digoxin ve İrinotectan adlı iki ilaçtan oluşan bir kombinasyon terapinin kolorektal kanser tedavisinde etkisini in vitro sistemde test etmektir. Diğer hedefi ise Digoxinin seçili hücre proliferasyon, apoptoz ve enflamasyon ile bağlantılı olan HCT 116 kolon kanser hücre zincirindeki anti-kanser etkisini incelemektir.

Sunulan çalışma için kardiyak glikozit olarak kullanılan Digoxin ile kemoterapi ilacı olan İrinotectan seçilmiştir. Öncelikle, HCT 116 hücreleri değişen Digoxin konsantrasyonları içeren hücre besiyeri ile inkübe edilip hücrelerin proliferasyon ve canlılığı ölçülmüştür. Digoxin'in konsantrasyona bağlı olarak yalnızca HCT 116 hücre hattının canlılığını engellemediği aynı zamanda apoptozu indüklediği de görülmüştür. Digoxin, İrinotecan ile aynı anda uygulandığında ise iki ilaç arasında çalışılan tüm konsantrasyon değerlerinde ve belirli oranlarda sinerjik bir etkinin olduğu saptanmıştır. Digoxin'in IC50 değeri 78 µM ve İrinotecan IC50 değeri 330 µM olarak belirlenmiştir. 94.99 µM İrinotecan, 68.8 µM Digoxin ile birlikte uygulandığında ise hücrelerin %55'inin canlılığını yitirdiği belirlenmiştir.

Elde edilen sonuçlar, Digoxin ve İrinotecan'dan oluşan kombinasyon terapinin kolon kanseri hücre hattındaki etkileri olumlu olduğunu göstermektedir. Bu sonuçlar bu iki ilacın kolorektal kanserinde ve diğer kanser çeşitlerinde yakın gelecekte daha etkin tedavi geliştirmek için kullanabileceklerini işaret etmektedir.

**Anahtar Kelimeler:** Digoxin, İrinotecan. Anti-kanser Ajan, Kolon kanseri

### **3. INTRODUCTION AND PURPOSE**

#### **3.1. Introduction**

Cancer is a fatal disease, which develops as result of rapid and uncontrolled division of cells. When this kind of abnormal development takes place in the colon or rectum it is regarded as colorectal cancer (CRC), which is characterized as the large intestine cancer. Colon (large bowel or large intestine) is a muscular pipe approximately 5 feet lengthypart of the digestive system that absorbs water and salts from the food, whereas rectum reaches 6 inches of the digestive system (1).

CRC is a cancer, which grows in one of two, the colon tissues, which represents the longest branch of the great intestine, and in the rectum tissues, which is the large section of the intestine ahead of the anus. CRC is one of the most important cause of cancer deaths globally. Nearly all CRC begins of a small development named polyp, such polyps are typically benign, but a few might grow as a cancer after long time, which may be more than 10 years. CRC is the second most common cancer in male and the third most common cancer in female population (2).

The occurrences of CRC differ extensively all over the world and the most frequent occurrence rates were found in developed countries particularly in Australia, New Zealand, Europe and North America, while the least incidence rates were found in Africa and Asia. These geographical discrepancies can be attributed to variances in dietary and environmental factors. Nevertheless, the occurrence rates of CRC are getting higher in newly developed countries. The increasing rates of cancers are attributed to Westernization of diet, rise in obesity, and inactivity (3).

Many factors such as age, the existence of polyps, inflammatory bowel illness, standard of living, and genetic background have been associated with the risk of CRC. Environmental factors like obesity, physical inactivity, poor diet, and smoking and profound alcohol utilization make up around 80% of all CRC conditions (4). While early

CRC might not show any signs, and indications of CRC mainly rely on its position and capability to metastasize (5,6).

The majority of drugs used for the treatment of cancer today are cytotoxic drugs that work by interfering in some way with the operation of the cell's DNA. Identification of cytotoxic compounds led the development of anti-cancer therapeutic for several decades. Advanced in cancer treatment, however continued to be limited by the identification of unique biochemical aspects of malignances that could be exploited to selectively target tumor cells (7).

Cardiac glycosides, aregroup of natural compounds, and are also important types of molecules for heart failure treatment. They have steroid like structures and inhibit membrane  $\text{Na}^+\text{-K}^+$  pump leading to activation of  $\text{Na}^+/\text{Ca}^{++}$  exchanger and elevation of intracellular Calcium. Eventually this leads positive intropic effects on cardiac muscle. Among cardiac glycosides, particularly Digoxin has been formerly known and used as an antiarrhythmic agent. In the 1960s, an obvious inhibition of cancer cells by cardiac glycosides was stated (8). In recent years, there are several studies proposed that cardiac glycosides also have anti-cancer effect (9). In the shed of this light, Digoxin's potential anticancer effects were investigated either by employing Digoxin alone or incombination with other agents(10). Antiproliferative, pro-apoptotic, and chemotherapy sensitization effects of Digoxin have been studied (8). Today, it is known that Digoxin inhibits proliferation of tumor cells when applied at optimal concentrations (11).

Irinotecan is a commonly used chemotherapy drug in clinics. It is generellay employed for the treatment of bowel cancer or CRC. Generally, it is used with other anti-cancer medicines. The mechanism of Irinotecan includes an enzyme known as topoisomerase, which takes role during DNA replication. Inhibition of this enzyme by Irinotecan, DNA replication halts, interfering with the synthesis of proteins required for cancer cell development and replication. Eventually, the cancer cell can not divide and proliferate (12).

### **3.1.1. Objectives**

The main objective of this study was to develop an *in vitro* cell culture combination therapy based assay to study the effect of Digoxin and Irinotecan on colon cancer treatment. Our long-term goal was:

1. To understand the family history characteristics associated with increased CRC risk and with inherited CRC syndromes.
2. To contribute the prolongation of patient's life, and life quality.
3. To help our understanding and improve knowledge of CRC.
4. To contribute to reduce mortality of cancer.

### **3.1.2 Problem statement**

Treatment choices for CRC include surgery, chemotherapy, radiotherapy or combination of more than one treatment. The drugs that are used in particularly in chemotherapy are toxic and have several drawbacks to healthy cells as well. Thus, there is a need for new treatment regimens that has minimum or no side effect. Using more than one type of drug and trying to catch a synergy in between them to get better treatment efficiency is a way to achieve this goal (13).

### **3.1.3 Purpose of the study**

The main purpose of this study was to plant seeds for a combination therapy for CRC employing two drugs that are already used in clinics. In order to achieve that goal, cell culture based assay used to study the effects of Digoxin and Irinotecan on CRC treatment using Human Colon cancer Type (HCT 116) colon carcinoma cell lines. Both of these drugs are used in clinics for different purposes as elaborated above. Employing varying concentrations of Digoxin and Irinotecan, we aim to obtain preliminary results for a new treatment strategy, which would offer synergism between the two drugs and would have minimum side effect.

### **3.1.4 Hypotheses**

1. Digoxin, proportional to its concentration, inhibits the growth of HCT 116 cells.
2. Irinotecan and Digoxin can be used concurrently in HCT 116 cell line to screen the cell viability of the cell.
3. It is possible to determine synergism in between Irinotecan and Digoxin for colon cancer.



## **4. GENERAL INFORMATION**

### **4.1 What is cancer?**

Cancer is defined as a fatal disease, which arises when variations in a group of normal cells inside the body inclined to unlimited growth causing formation of a lump called a tumor. This description is applicable to all cancers except Hematological cancers. If the affected cells left untreated, tumors may develop and anchoring to the healthy tissue, or to further spread (metastasis) of the tumor might be possible through bloodstream and lymphatic system.

Health cells in human body are continuously split, differentiate into another cell or recycled based on the variety of signals and pathways. However, cancer cells grow independtly from these signaling which yields unlimited development and proliferation. If this proliferation is left untreated and allowed to spread, it may be serious or incurable, as it is known that 90% of cancer associated deaths are due to tumor spread (14).

Cancer is also a disease which may happen again or persist during the lifetime of the cancer patient, some cancer patients are never entirely free of the disease whereas other cancer patients may free of the disease after medication or may be in remission and then the cancer may return. Although cancer encompasses at least varying diseases, all cancer cells have a significant attribute, they are nonstandard cells in which normal cell division disrupted, and also cancer grows from modifications that cause normal cells to gain abnormal functions.

These modifications are often the outcome of inherited mutation or came from environmental causes. Also the majority of cancers are not come from one particular incident or factor, cancer cells have nature of unlimited cell development, and also have capability to attack their close tissues and eventually to create metastasis in remote spaces of human body.



Gene mutation or deregulation also helps cell movement that is highly related with tissue attack and the formation of remote metastasis. Cancer from a series of molecular events that basically change the ordinary characteristics of the cell, in cancer cells the normal control systems that stop cell overgrowth and attack of other tissues are put out of action (15).

Despite different types of cancer, which are more than one hundred sorts, a number of similarities that are general to the majority of cancers have been determined. Healthy tissues cautiously control proliferative stimuli, which are conveyed by indicating pathways and rule cell development and division symptoms. These indicating pathways in the cancer cells are often changed, exposing cancer cells to proliferate autonomously. However, unrolled proliferation needs not only the presence of improved proliferative indications but also inactivation of the mechanisms that limit cell proliferation (16).

It is commonly accepted that cancer cells need unlimited replication potential as to produce macroscopic tumors. In healthy tissues, the replication capability is restricted by two major mechanisms. The first one is senescence which preserves cells in a resting but viable condition. The second one is crisis which engages cell loss. The capability of cancer cells to conquer these limitative processes has been demonstrated immortalization, and the enzyme telomerase constitutes a fundamental function in this procedure and is linked with a resistance to initiation of both these mechanisms.

The mortality of cancer depends on the ability of cancer cells for dispersion to other branches of the human body in a multistep process of attacking and metastasis. This process consists of a chain of cell alteration, starting with local invasion, then intravasation into close by blood and lymphatic vessels. Finally the growth of micro metastasis lesions into macroscopic tumors and turn into colonization. Also cancer cells grow alterations in their form as well as in their connection to other cells and to the extracellular matrix. There are a lot of diverse kinds of malignant tumors being

determined but more than 50% of recently diagnosed cancers occur in five main organs such as lungs, colon/rectum, breast, prostate, and uterus.

Cancers of the lungs, colon/rectum and prostate are the principal most important causes of deaths in men and in women, breast, colorectal and uterine cancers are the most widespread (17).

## **4.2 Morphological and biochemical changes**

In comparison to healthy cells, there are several morphological and biochemical changes in cancer cells.

### **4.2.1 Morphological changes**

- ❖ Have usually rounded shape, larger than health cells.
- ❖ Cells show nuclear and cellular pleomorphism, hyperchromatism, altered nuclear: cytoplasmic ratio, abundant mitosis, sometimes tumor giant cells.
- ❖ Transformed cells often grow over one another and form multilayers.
- ❖ Can grow without attachment to the surface in vitro, diminished adhesion.

### **4.2.2 Biochemical changes**

- ❖ Increased formation of DNA and RNA.
- ❖ Show increased rate of glycolysis both aerobic and anaerobic.
- ❖ Show alterations of permeability and surface charge.
- ❖ Changes in composition of glycoproteins and glycosphingolipids on cell surfaces.
- ❖ Alterations of the oligosaccharide chains.
- ❖ Increased activity of ribonucleotide reductase and decreased catabolism of pyrimidines.
- ❖ Secretion of certain proteases and protein kinases.
- ❖ Alterations of isoenzyme patterns often to a foetal pattern and synthesis of foetal proteins, e.g. carcinoembryonic antigen (CEA),  $\alpha$ -fetoprotein (AFP), etc.
- ❖ Appearance of new antigens and loss of certain antigens (18).

### **4.3 Types of cancer**

Cancers are categorized into diverse sorts (Carcinomas, Sarcomas, Lymphomas and Leukemia's), relying on which tissues they originate from by the type of cell that the tumor cells come from (19, 20).

#### **4.3.1 Carcinomas**

Carcinomas are cancers that initiate in the epithelial tissues, epithelial cells are the cells that covering the outside of the body as well as the inside parts and cavities, carcinomas might influence the breast, lung, prostate, and colon are also in the midst of the most general sorts of cancer in adults.

- Carcinoma which affect the adrenal glands.
- Carcinoma which affects the thyroid gland.
- Carcinoma which affects the nose and pharynx.
- Malignant melanoma which describes skin cancer.
- Skin carcinoma other than melanoma.
- Other carcinomas including those affecting the salivary gland, colon, appendix, lung and bronchus, cervix, and urinary bladder.

#### **4.3.2 Sarcoma**

Cancers of the connective tissue are labeled Sarcomas. This kind of cancer grows in the connective tissue of the body include, fat, blood vessels, nerves, bones, muscles, deep skin tissues, and cartilage (21).

#### **4.3.3 Lymphoma**

Lymphoma is a cancer that develops in the white blood cells, which is part of body's immune system. There are two major types of lymphoma: Hodgkin (HL) and non-Hodgkin (NHL) lymphoma (22).

#### **4.3.4 Leukemia**

Leukemia is also a cancer of white blood cells, but some leukemia begin in other blood cell sorts, signs of entire kinds of leukemia are associated to reproduction of nonstandard blood cells and substitution of the bone marrow by cancerous cells (23).

#### **4.4 Cancer cell metabolism**

Metabolism is the group of life-maintaining chemical revolutions inside the cells of living organisms. These interactions or enzyme-catalyzed reactions permit organisms to develop and reproduce, sustain their composition, and respond to their surroundings. All the cells in our body need specific molecules that can either be burned to create energy (catabolism) or utilized to produce building blocks of the basic structure to maintain proliferation (anabolism).

In relation to prerequisites of nutrients are mainly essential in reproducing cells, because they require to conserve their integrity and execute their physiological tasks and to produce a fresh daughter cell as well (24).

Cancer cells are distinguished by modifications in cell metabolism together with greater glucose consumption and aerobic glycolysis, normally known as the “Warburg effect” (25). Cancer cells change their metabolism as to hold up their fast reproduction and spreading out through the body. Typical cell replication in the tissues is restricted by the accessibility of growth controlling factors and by the interaction with nearby cells.

The accessibility of nutrients and oxygen, needed for cell replication and metabolism, mainly relies on blood supply, because early tumor development happens in the absence of creation of new blood vessels. Tumor cells have a greatly advanced rate of glucose use through a glycolysis pathway which does not provide pyruvate to the Krebs cycle but that instead changes pyruvate to lactate, many tumors consume this

glucose to lactate pathway even in the existence of oxygen, illustrating why the term aerobic glycolysis is frequently employed as an alternative to the Warburg effect (25).

#### **4.4.1 Metabolic alterations associated with cancer**

Cancer cells displayed major changes in energy metabolism and mitochondrial respiration weighed against ordinary cells, also cancer cells actively utilized glycolysis for ATP production, even in the existence of an abundant supply of oxygen. Although whether metabolic changes cause tumor genesis or are a consequence of transformation is still under discussion, but great reliance on glycolysis is seen in the most of tumors and that glycolysis gives ATP in addition to the metabolic intermediates necessary for cancer cell proliferation and tumor growth.

Metabolic intermediates produced through glycolysis offer significant basics or foundations for the synthesis of DNA, fatty acids and for redox control. For example, glucose-6-phosphate, the product of the first glycolytic reaction, may be channeled to the pentose phosphate pathway (PPP) to produce ribose5phosphate and nicotinamide adenine dinucleotide phosphate (NADPH), which are significant for nucleic acid metabolism and redox homeostasis, respectively.

NADPH and three carbon metabolic intermediates are also essential for lipid biosynthesis. Last but not least, the high levels of lactic acid generated during glycolysis might activate metalloproteinase and matrix remodeling enzymes, therefore resulting cancer metastasis (26).

#### **4.4.2 Regulation of cancer cell metabolism**

The cells of the cancer show metabolic phenotypes, which differentiate them from ordinary tissue cells, in specifically an improved activity of metabolic pathways are essential for cell development. In turn, accumulating evidence presents that major oncogenes, for instance, Ras and Myc, positively control metabolic pathways that are up regulated in cancer cells.

Cancer cells obtain alterations to the metabolism of all four main classes of macromolecules carbohydrates, proteins, lipids and nucleic acids. Several comparable alterations are also seen in quickly proliferating normal cells, in which they stand for suitable reactions to physiological development indications as opposed to constitutive cell autonomous adaptations (27).

According to cancer cells, these adaptations should be executed in the stressful and dynamic microenvironment of the solid tumor, where concentrations of critical nutrients like glucose, glutamine and oxygen are temporally heterogeneous. The character and significance of metabolic response in cancer has often been made owing to the use of tissue culture circumstances in which both oxygen and nutrients are constantly in surplus.

Malignant conversion of cells needs definite adaptations of cellular metabolism to hold up development and survival. In the early twentieth century, Otto Warburg recognized that there is elementary dissimilarity in the central metabolic pathways working in malignant tissue. He displayed that cancer cells use a large amount of glucose, sustain high rate of glycolysis and alter a majority of glucose into lactic acid even under normal oxygen concentrations (28).

#### **4.4.3 Hypoxia and cancer cell metabolism**

Hypoxia is a situation where in the human body or an area of the human body is deprived of sufficient oxygen. Hypoxia is frequently a pathological situation. The environmental stress of hypoxia activates molecular alterations that make easy metabolic adaptations. Some of such changes are up-regulated glycolytic enzyme expression along with oxidative phosphorylation inhibition, mitochondrial selective autophagy, and glucose, citrate creation for fatty acid synthesis (29).

Hypoxia-inducible factor (HIF) activation is the most recognized and distinguished molecular reaction running many of these changed metabolic pathways of hypoxia. It has been revealed in the recent few years that oncogenes discovered in an extensive diversity of human cancers can directly activate Hypoxia and other elements of glucose metabolism autonomously of hypoxia (30).

#### **4.4.4 Metabolic signaling in cancer cells**

Mitochondrial metabolic signaling (MMS) can be defined as the regulation of cellular gene expression by various (energy) metabolites and by-products that accumulate upstream or downstream of the mitochondrion. The feedback of this process takes place under physiological situations and contributes to the control of cell homeostasis, as well as the diverse pathologies MMS is altered by the abnormal accumulation of indicating metabolites, which interferes with physiological processes and contributes to the progression of the illness and also phenotypic variability.

As mitochondria hosts an excess of cellular metabolic reactions, this organelle is essential for metabolic signaling, like vascular endothelial growth factor, and glucose transporter, which are engaged in the support of tumor proliferation through a redefinition of the metabolic profile (26).

#### **4.4.5 Metabolic behavior of cancer cells**

Cancer cells attain an abnormal glycolytic behavior relative to a large extent, to their intracellular alkaline pH. This effect is part of the metabolic changes obtained in most, if not all, cancer cells to deal with adverse situations, primarily hypoxia and low nutrient supply, in order to conserve its evolutionary trajectory with the production of lactate after ten steps of glycolysis. Therefore, cancer cells reprogram their cellular metabolism in a way that provides them their evolutionary and thermodynamic benefit. Tumors have highly heterogeneous microenvironment and cancer cells survive within any of the various habitats that lie within tumors (31).

## **4.5 CRC**

Among various cancer types, CRC is a cancer that develops either in the tissues of the colon, the longest part of the large intestine, or in the tissues of the rectum, the least part of the large intestine before the anus (32). Genetics, hormonal changes, environmental factors, alcohol, weight, age, physical activity and diet has role in the development of CRC (33, 34, 35, 36, 37, 38, 39, 40, 41, 42).

## **4.6 Apoptosis**

Apoptosis is a Greek origin, which means "falling off or dropping off" (43). Apoptosis is described as a morphologic alteration resulting in controlled cellular self-destruction by a process obviously different from necrosis. Since the 19th century, several studies have displayed that cell loss contributes to throughout physiological progression of multicellular organisms, especially through embryogenesis and metamorphosis (44).

The apoptotic form of cell loss is an active and described process, which plays a significant role in the development of multicellular organisms and in the control and protection of the cell populations in tissues upon physiological and pathological situations. Cell loss is a necessary part of the usual growth and persists into adulthood. Apoptosis contributes to a crucial part in limiting a lot of cells in development and during the life of an organism by the elimination of cells at the suitable moment.

Changes of this regular process may lead to the disturbance of the slight balance between cell replication and cell loss as well as could result in a diversity of diseases. For instance, in several types of cancer, most important proapoptotic proteins are mutated or antiapoptotic proteins are up controlled, causing the accumulation of cells and the incapability to react to damaging mutations, DNA damage, or chemotherapeutic agents (45).



#### **4.6.1 Features of apoptosis**

Cell loss might take place through at least two generally described mechanisms: necrosis or apoptosis. Necrosis is a passive, catabolic, pathological cell death process which commonly happens in reaction to external toxic factors like inflammation, ischaemic or toxic injury. It is not thought to ever happen under physiological situations. On the other hand, apoptosis is an active, metabolic, genetically encoded and evolutionarily chosen death pathway. It takes place under either physiological or pathological situations (46).

#### **4.6.2 Significance of apoptosis**

The growth and preservation of multicellular biological systems rely on complicated interaction among the cells composing the organism. It occasionally tends to engage an altruistic performance of individual cells in favor of the organism. As a whole, apoptotic processes are common biological importance, being engaged in e.g. growth, differentiation, replication/homoeostasis, control and function of the immune system. Therefore, dysfunction or dysregulation of the apoptotic program is implicated in a variety of pathological situations (47).

#### **4.6.3 Correlation between apoptosis and proliferation**

The balance between cell proliferation and cell death throughout apoptosis identifies how fast a tumor develops. Most colorectal adenomas are steady for a longtime before, if ever, altering to malignancies. Traditionally, an increase in cell replication, rather than a change in apoptosis, has been used to forecast later tumor growth and prognosis. Nevertheless, in an animal model, the best estimator of tumour development was the level of apoptosis, whereas there is common conformity that deregulation of apoptosis plays a significant role in malignant transformation. The potential estimated or prognostic value of the level of apoptosis in CRC is in question (48).


## **4.7 Treatment of cancer**

Treatment is the series of contribution, including psychosocial help, surgery, radiotherapy, and chemotherapy that is targeted curing the disease or significantly prolonging life and life quality of patient. Cancer diagnosis is the first step to cancer management. It includes combination of cautious clinical evaluation and diagnostic examinations together with endoscopy, imaging, histopathology, cytology and laboratory researches (13).

Treatment of cancer, especially CRC, might require surgery, chemotherapy (use of anti-cancer drugs), or radiotherapy (use of x-ray to target and kill cancer cells), hormonal therapy alone or in combination (49). CRC treatment may be managed towards three different phases of the illness. The first is the tumor development, the second is the original cancer tissue and the third is the systemic disease. In the near future, the greatest advantage in CRC treatment might not be at the degree of the primary tumor, but in identifying initial steps in disease progress with respect to prevention, initial discovery and treatment (50). One of the most frequent and advantageous chemotherapeutic drugs used for colon cancer is Irinotecan and the treatment efficiency is dose dependent (51).

### **4.7.1 What is Irinotecan?**

Irinotecan is a chemotherapy agent for bowel cancer and CRC. It is typically used in combination with other anti-cancer medicines. Irinotecan works by inhibiting an enzyme known as topoisomerase. It is an essential enzyme for cells since they require this enzyme to proliferate and develop as of two new cells. The rule applies to healthy cells as well as cancer cells. During cancer treatment, Irinotecan inhibits this enzyme, then the DNA of cells becomes tangled up and the cancer cells cannot divide (52).



**Figure 4.7.1** Structure of Irinotecan

For more than three decades, the therapeutic choices for patients with complex CRC have almost completely been rooted in fluoropyrimidines. With the determination that topoisomerase-I (TOP-I) is a significant therapeutic target in cancer therapy, Irinotecan, a semisynthetic TOP-I-interactive camptothecin derivative, has been clinically established in the treatment of CRC. (53).

Irinotecan is an anti-cancer chemotherapy agent. This drug is known as a "plant alkaloid" and/or "topoisomerase I inhibitor." It is a topoisomerase I inhibitor used to treat variety of solid tumors and it is being usually used in combination with other chemotherapeutic agents for the treatment of CRC. (54). The dose of irinotecan that patient receives rely on many factors such as height and weight, general health and/or other health problems as well as the stage of the cancer being treated. (55).

Chemotherapy treatments are the most effective when provided in other drugs in combination chemotherapy. As it is concluded from the results that were obtained in this thesis as well, the foundation for combination chemotherapy is to utilize medications that function by diversified mechanisms, consequently diminishing the chance that

resistant cancer cells will grow. When treatments with diverse impacts are joined, each drug can be used at its optimal dose, without intolerable side effects. (56).

#### **4.7.1.1 How Irinotecan Works:**

Cancerous tumors are attributed to cell division and grow, which is no longer limited as it is in normal tissue. "Normal" cells control/prevent proliferation when they come into contact with such cells, a mechanism labeled as contact inhibition. Cancerous cells lose this capacity. Cancer cells no longer have the normal check points for cell cycle and balances in place that control and limit cell division. The progress of cell splitting up, whether regular or cancerous cells, is throughout the cell cycle. The cell cycle leaves from the inactive phase, through active developing phases, and then to mitosis (division). The capacity of chemotherapy to eliminate cancer cells relays on its capability to stop cell division. Generally, the treatments work by damaging the RNA or DNA that alerts the cell how to copy itself in division. If the cells could not split, they would die. The quicker the cells are splitting up, the more possibly it is that chemotherapy will eliminate the cells, resulting the tumor to contract. They also induce cell suicide (self-death or apoptosis) (55). Irinotecan follows the similar mechanism, inhibition of TOP-I, to stop cell proliferation


#### **4.7.1.2 Side effects of Irinotecan**

Like other chemotherapy agents, Irinotecan has several side effects which lowers life quality of cancer patient (57). These side effects includes but not limited to

- Increased sweating
- Diarrhea
- Increased production of saliva
- Watery eyes
- Abdominal cramps

### 4.7.2 Digoxin

Digoxin is one of the cardiac glycosides that directly associated with a collection of medicines having in common definite impacts on the myocardium (muscular wall of the heart). Digoxin contains steroidal nucleus and sugar at position 17 (Figure: 4.7.2). The attached sugars such as glucose, galactose, mannose, and digitalose identify the pharmacodynamic and pharmacokinetic actions of each cardiac glycosides. Digoxin is used in the treatment of cardiac pathology like atrial fibrillation and heart failure (58).



**Figure: 4.7.2** Structure of Digoxin


Cardiac glycosides are a group of naturally happening compounds with a steroid like structure can inhibit  $\text{Na}^+\text{-K}^+$  ATPase, which can lead to activation of  $\text{Na}^+/\text{Ca}^{++}$  exchanger and elevation of intracellular Calcium, and eventually lead a positive inotropic effects on cardiac muscle. Digitoxin and Digoxin are the two commonly prescribed cardiac glycosides. Chemical structures of these two glycosides have three essential structural elements: an unsaturated lactone ring, a steroid nucleus, and many sugar moieties (which mainly effect the pharmacokinetic properties). Digoxin has an additional hydroxyl group compared to Digitoxin (59). Digitalis Glycosides have different properties as shown in Table 4.7.3.

**Table: 4.7.3** Properties of Digitalis Glycosides

<b>Property</b>	<b>Digoxin</b>	<b>Digitoxin</b>
Lipid Solubility	Medium	High
Oral Absorption	75%	>90%
Plasma Protein Binding	20-40%	>90%
Plasma Half-Life	1.6 days	7 days
Route of Elimination	Kidney	Liver

Despite their different structure, both of them are inhibitors of the plasma membrane  $\text{Na}^+\text{-K}^+\text{-ATPase}$ . As they inhibit  $\text{Na}^+\text{-K}^+\text{-ATPase}$ , intracellular  $\text{Na}^+$  concentration increases while intracellular  $\text{K}^+$  concentration decreases, resulting in an increase in cardiac contraction. This action acts as the synthesizing of signaling molecules like Caveolin, SRC kinase, epidermal growth factor receptor (EGFR) and the inositol triphosphate receptor. The inhibitory effects of cardiac glycosides on  $\text{Na}^+\text{-K}^+\text{-ATPase}$  could account the biological properties of these compounds including their anticancer activities (60).

The mechanism whereby cardiac glycosides lead to a positive inotropic impact and electrophysiological alterations is still not entirely clear. Many mechanisms have been projected, but the main generally agreed engages the capability of cardiac glycosides to hold back the membrane bound  $\text{Na}^+\text{-K}^+\text{-ATPase}$  pump in charge of  $\text{Na}^+\text{-K}^+$  exchange (61). The process of muscle contraction may be depicted as shown in Figure: 4.7.4.



**Figure: 4.7.4** Biochemical mechanism of action

#### 4.7.2.1 Anti-cancer and Anti-proliferative effects properties of digoxin

Several studies proposed that cardiac glycosides can have anticancer characteristics. Also Digoxin inhibit proliferation of human tumor cells when applied at optimal concentrations (11).

Increased rate of cell proliferation is hallmark of cancer development. Cardiac glycosides have anti-proliferative activities through their control of the cell cycle. Anti-proliferative impacts of cardiac glycosides against human breast and prostate cancer cells have also been stated (62). The growing of intracellular calcium concentration followed treatment with digoxin is related to the anti-proliferative impacts of this composite in androgen-reliant and androgen-autonomous prostate cancer cell lines (63).

#### **4.7.2.2 Cardiac glycosides in cancer treatment**

Preclinical and clinical data recommend that Digoxin may be used as anti-cancer agent in cancer therapy. In addition, recent reports have shown that Digoxin can prevent development of cells and induce apoptosis in cancer cells at certain concentrations recommended for cardiac patients. Cardiac glycosides used for the medication of cardiac problems might also be beneficial as anticancer agents (64).

Several epidemiological researches concluded that Digoxin is effective in a lot of cancers including lung, colon, prostate, and ovary. However, among middle aged women using Digoxin, breast cancer and uterus cancers rates have increased since both of these cancers are often estrogen-sensitive (60, 65).

#### **4.7.2.3 Digoxin toxicity**

Digoxin toxicity takes place when Digoxin concentration exceeds tolerable limits in a human body. Digoxin toxicity causes hyperkalemia, which is known as high potassium concentration in blood. The sodium/potassium ATPase pump push sodium out of the cell and uptake potassium from the cellular fluid into the cell. Blockage of this mechanism results in high potassium levels in blood and eventually to hyperkalemia. Digoxin toxicity is declined in condition called hypokalemia (low potassium level in blood) since Digoxin competes with potassium to bind to the ATPase pump on the same location. When potassium levels are low, digoxin can more simply attach to the ATPase pump and its inhibitor function gains great impacts. There are some factors such as age, kidney diseases, hypothyroidism, heart disease and use of medicines that interact with digoxin that increase the risk for digoxin toxicity (66).

#### **4.7.2.4 Side effects of digoxin**

The major reactions of digoxin arise when there is an excess of it in the blood stream. These impacts may range from gastrointestinal impacts like appetite, abdominal pain, intestinal ischemia, hemorrhagic necrosis of the intestines, vomiting, and diarrhea



or behavior changes to severe heart abnormalities. Furthermore, digoxin might bring about visual disturbances, headache, weakness, dizziness, apathy, confusion, mental disturbances, and skin reaction (67).

#### **4.7.2.5 Metabolism and excretion of digoxin**

Following intravenous administration of Digoxin to healthy volunteers, 50% to 70% of the drug dose is excreted unaltered way in the urine. In healthy volunteers with healthy renal function, digoxin has a half-life of 1,6 to 2 days. The urinary metabolites, which encompasses, digoxigenin bisdigitoxoside, dihydrodigoxin and their glucuronide as well as sulfate conjugates, are polar in nature and are believed to form as a result of hydrolysis, oxidation, and conjugation (68).

#### **4.7.3 Combination therapy**

The overall goal of cancer therapy is to destroy all the cancer cells at the same time with minimal harm to the healthy tissue. This may be reached in several ways, either directly or indirectly by depriving the cancer cells of signals required for cellular replication or by stimulating an immune reaction. Combination therapy is one way to improve effectiveness of the cancer treatment (69).

Combination therapy is a wide expression for the use of various treatments or therapies as to fight the one single disease. Although it normally represents the use of two or more medicines, it may also include immunotherapy, radiotherapy, chemotherapy, surgery, non-medical therapies along with psychological support.

The practice of combination therapy especially for cancer patients is not new. Combination therapy may provide an obvious benefit to the patient. For instance, while one medicine might be used to reduce inflammation or slow down the development of disease, another may directly devastate the foreign cells. Therefore, in order to get best outcome, it is beneficial to apply more than one therapy to treat cancer

like diseases (70). Over the past decade, since many doctors, oncologists, and other medical professionals suggest combination therapies for a variety of diseases and conditions, the number of accepted and examined combination therapies significantly raises. The use of more than one kind of therapy is a hallmark of cancer medication. The complexity of the disease, rate of metastasis, fast advancement in stages, as well as its genetic variety highlights the need for a different of methods to invade it. For well over half a century, physicians have had three major sorts of cancer medications: surgery, radiotherapy, and chemotherapy. The use of a definite treatment or combination of treatments relays on an array of aspects, including the type of cancer, its aggressiveness, and it's potential to metastasize, or spread to other parts of the body. With today's technology and knowledge, it is essential to identify how this method can assist in treatment of various cancer types with minimal side effects to the patient (71).

Combination therapy, a type of treatment that unites two or more therapeutic agents, is a foundation of cancer therapy (72). The mixture of anti-cancer treatments improves efficiency weighed against the mono-therapy method since it aims at significant and/or different pathways in a characteristically synergistic or an additive way. This way mainly diminishes drug resistance, whereas concurrently offering therapeutic anti-cancer advantages, such as degreasing tumor development and metastatic potential, arresting mitotically active cells, degreasing cancer stem cell populations, and inducing apoptosis (73).

The complication of the disease, its inclination to extend outside of its original place, and development of resistance to definite treatments as well as its genetic variety highlights the necessity for a diversity of methods to attack it. In several situations, combination therapy not only raises the probability of a treatment or long-term remission, but also diminishes harm to essential organs and tissues more than a single method (74).

For almost more than half a century, physicians have had three major sorts of cancer medications in their arsenal: surgery, radiation therapy, and chemo-, or drug, therapy. The use of a specific medication or mixture of medications relies on a range of aspects, together with the kind of cancer, its aggressiveness, and its potential to metastasize, or extend to other branches of the body. As a common law, solid tumors (which shape masses within individual organs) are typically cured by surgery, if limited to the place they began in, and/or radiation therapy to take away or decrease the tumor, followed by chemotherapy to remove any residual tumor cells. Blood-associated cancers such as leukemia, lymphoma, and multiple myeloma are commonly cured by chemotherapy agents and/or radiation therapy since the disease is dispersed over wide parts of the body (73).

One sort of treatment may occasionally formulate a tumor more susceptible to a second sort. Specific chemotherapy treatments, for instance, may raise tumors' susceptibility to radiation therapy. In other conditions, treatments work together, each improving the others' strength, so their joint effectiveness is superior than would be forecasted by their individual effect. Combinations of diverse chemotherapy agents are often employed to obstruct cancer's "escape routes." A tumor that develops into resistant to one chemotherapy agent might surrender to treatment with a second or third. (75).

In the latest years, a diversity of latest treatments has been commenced that supplement the traditional triad of surgery, radiation therapy, and chemotherapy. These comprise "targeted" drugs that zero in on specific irregular genes or proteins in tumor cells, anti-angiogenic drugs that stop tumors from siphoning off nutrients from the bloodstream to maintain their unrestricted development, that impede cancer cells' capability to refurbish smashed DNA, and immunotherapy agents that promote an immune system attack on tumors. (76).

Over a half-century has gone since cancer chemotherapy started. The chemotherapy agents now in use initiated as biologically targeted therapy. Hitchings and

Elion built up certain inhibitors of purine synthesis, such as 6-MP; Heidelberger targeted RNA synthesis with 5-FU; and Farber targeted the reduced folate pathway with aminopterin (77). These improvements not only offered the basis for cancer medication but also turned into tools for finding of the basic workings of transformed cancer cells. Natural products like the Vinca alkaloids, anthracyclines, and taxanes were chosen specially for activity against cancer propagation. These agents were joined with other classes of agents, such as hormones, alkylating agents, and irradiation that are active against reproducing cells. (78).

For several cancers, the most excellent methodology is a combination of surgery, radiation therapy, and/or chemotherapy. Surgery or radiation therapy cures cancer that is limited to its site, whereas chemotherapy also eliminates the cancer cells that have extended to remote places. Sometimes radiation therapy or chemotherapy is provided before surgery to contract a tumor, as a result leading the opportunity for complete surgical elimination. Radiation therapy and low-dose chemotherapy after surgery assist to devastate any residual cancer cells. The stage and type of the cancer frequently reveals whether single therapy or amalgamation therapy is required. For instance, early-stage breast cancer might be cured with surgery alone or surgery joined with radiation therapy, chemotherapy, or with all three medications, relying on the size of the tumor and the exposure of reappearance. For instance, locally advanced breast cancer is commonly cured with chemotherapy, radiation therapy, and surgery (79).

Sometimes combination chemotherapy is employed not to treat but to diminish signs and prolong life. Combination chemotherapy can be helpful for people with complex cancers that are not appropriate for radiation therapy or surgical treatment (for example, people with non-small cell lung cancer, esophageal cancer, or bladder cancer that cannot be entirely eliminated by surgery) (80).

Combinations of diverse chemotherapy agents are regularly utilized to block cancer's "escape routes." A tumor that turns into resistant to one chemotherapy agent may succumb to treatment with a second or third. In many conditions, combination

therapy not only increases the chances of a cure or long-term remission, but also reduces damage to vital organs and tissues more than a single approach. The stage and type of the cancer often identifies whether single therapy or combination therapy is necessary. For instance, early-stage breast cancer might be healed with surgery alone or surgery combined with radiation therapy, chemotherapy, or with all three medications, relaying on the size of the tumor and the danger of repetition. (81)

Chemotherapy treatments that influence cells only when they are splitting up are called cell-cycle specific. Chemotherapy treatments that influence cells when they are at rest are called cell-cycle non-specific. The scheduling of chemotherapy is set according to the sort of cells, rate at which they split up, and the time at which a given drug is expected to be effective. This is the reason why chemotherapy is usually given in cycles. Chemotherapy is mainly efficeint at eliminating cells that are quickly splitting up. Unfortunately, chemotherapy does not determine the difference between the cancerous cells and the regular cells. The "normal" cells will develop back and be healthy but in the meantime, side effects happen. The "normal" cells most generally affected by chemotherapy are the blood cells, the cells in the mouth, stomach and bowel, and the hair follicles; resulting in low blood counts, mouth sores, nausea, diarrhea, and/or hair loss. Different drugs may affect different parts of the body (55).

Occasionally combination chemotherapy is used not to cure but to diminish signs and prolong life. Combination chemotherapy can be helpful for people with complex cancers that are not suitable for radiation therapy or surgical treatment (for example, people with non–small cell lung cancer, esophageal cancer, or bladder cancer that cannot be completely removed by surgery) (81).

## 5. MATERIAL AND METHOD

### 5.1 Material

This study of HCT116 involving routine cell culture was analysed in the Medipol University Laboratory by using the following Solutions and chemicals;

- HCT 116, Human Colon Cancer Cell Line (ATCC)
- DMEM with L-Glutamine (CAPRICORN)
- Fetal Bovine Serum (FBS) (BIOWEST)
- Phosphate-Buffered Saline (PBS) (CAPRICORN)
- Antibiotic (penicillin-streptomycin)
- Trypsin- EDTA (0.05%) in DPBS (CAPRICORN)
- Dimethyl sulphoxide (DMSO) (MERCK)
- MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)
- SpectraMax Plate Reader
- Digoxin ( $C_{41}H_{64}O_{14}$ )
- Irinotecan ( $C_{33}H_{38}N_4O_6$ )

### 5.2 METHOD

#### 5.2.1 Cell Culture Experiments

HCT-116 human colon cancer cell line is cultured by the DMEM medium with 10% FBS (fetal bovine serum) and 100U/ml Penicillin/Streptomycin under the cell culture conditions. Cells are passaged in every three days.

#### 5.2.2 Digoxin Cytotoxicity

HCT-116 human colon cancer cells seeded into 96 well plates by 10 000 cells/well and incubated 24 hours for complete adhesion. 7 different Digoxin solutions prepared between 0.001  $\mu$ M to 20  $\mu$ M concentration and in every well 200  $\mu$ l related concentration was applied, incubated for 24 hours. One well was marked as control

group, treated with only complete medium and another one is as positive control and treated with %0.25 Triton-X. All experiments repeated in triplicate. After incubation, medium with Digoxin is removed and changed with 200  $\mu$ L fresh medium with 5 ng MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide). Cells were incubated with MTT solution at 37 C for 3 hours. Then MTT solution removed and 200  $\mu$ L DMSO was added to all wells. After shaking at 300 rpm for 20 minutes to provide full dissolution of formazan and absorbance is measured at 570 nm by plate reader.

### **5.2.3 Irinotecan Cytotoxicity**


HCT-116 human colon cancer cells seeded into 96 well plates by 10 000 cells/well and incubated 24 hours for complete adhesion. 7 different Irinotecan solutions prepared between 0.1  $\mu$ M and 500  $\mu$ M and in every well 200  $\mu$ l related concentration was applied, incubated for 24 hours. 1 well was marked as control group, treated with only complete medium and another one is as positive control and treated with %0.25 Triton-X. All experiments were done in triplicate. After treatment, medium with digoxin is removed from cells and changed with 200  $\mu$ L medium with 5 ng MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide). Cells was incubated with MTT solution at 37 C for 3 hours. Then MTT solution removed and 200  $\mu$ L DMSO was added to all well shaken at 300 rpm 20 minutes to provide full dissolution of formazan and absorbance is measured at 570 nm by plate reader.

### **5.2.4 IC50 Determination and Analysis**

The drug concentrations used in most of the combination studies were based on the IC50 values, which are characterized as the drug concentration responsible for 50% growth inhibition. In this study, GraphPad Prism 6 was used to determine IC50 values and to produce following graphs. For determination of these data, untreated cell control group is accepted as 100 and Triton-X treated control group was accepted as 0. By this process other absorbance values were normalised and became comparable results. According to the IC50 values of each drug combination therapy experiment was set up.

### 5.2.5 Combination Therapy

HCT-116 human colon cancer cells seeded into 96 well plates by 10 000 cells/well and incubated 24 hours for complete adhesion. 10 different concentration points has been applied between 0.187X and 6X where X is IC50 values for each drug (Figure 5.2.5). Drugs were applied to the cells both at the same time, this condition requires 2 times more concentrated solutions for each drug since same time application causing volume decreasing to the half of the usual volume. After the treatment, medium with drug combination is removed from cells and changed with 200  $\mu$ L medium with 5 ng MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide). Cells were incubated with MTT solution at 37 C for 3 hours. Then MTT solution removed and 200  $\mu$ L DMSO was added to all well shaken at 300 rpm 20 minutes to provide full dissolution of formazan and absorbance is measured at 570 nm by plate reader. Results were evaluated in CompuSyn program.



**Figure: 5.2.5** This is showing concentration of Digoxin, Irinotecan, and combination of both drugs, also IC50 values, concentration (or dose) required to inhibit (or to affect) a system by 50%.


### 5.2.6 CompuSyn Analysis

The analysis of effect of obtained results between separately applied treatments for each drug and combinational therapy was determined by Prof. Chou's directions (Chou and Martin, 2005) CompuSyn program.




## 6. RESULTS


After the application of 7 different concentrations (0.001  $\mu\text{M}$  to 20  $\mu\text{M}$ ) of Digoxin and (0.1  $\mu\text{M}$  -500  $\mu\text{M}$ ) Irinotecan, results was normalized and graphs were drawn (Figure 6a and Figure 6b) on HCT-116 we obtained from the results, the effect between drug molecules separately and the combinative application (Figure 6.2). The IC<sub>50</sub> values (concentration required to reduce the initial cell number by 50%) of Digoxin and Irinotecan were calculated 78  $\mu\text{M}$  and 330  $\mu\text{M}$  respectively. To apply combination therapy we need to apply drugs at these IC<sub>50</sub> concentrations and by the help of CompuSyn program, the effect of thee combination therapy (synergism, antagonism or additive) and clinical beneficially became clear. Combination therapy was used in a constant ratio as it was mentioned above and according to the IC<sub>50</sub> values ratio was calculated as 1:4.25 (78  $\mu\text{M}$ : 330  $\mu\text{M}$ ).



**Figure 6:** HCT 116 human colon cancer cell viability after a) digoxin treatment with 24 hour incubation b) Irinotecan treatment with 24 hour incubation




**Figure:6.1:** HCT 116 colon cancer under the light microscope images of cells a) After 24 hours after Digoxin incubation (20x), (b)Before incubation with Digoxin (40x), (c) 24 hours after Digoxin incubation (10x) (d)24 hours after DMSO application (10x)



**Figure 6.2:**HCT 116 human colon cancer cell viability after combination therapy of Digoxin and Irinotecan at constant ratio of 1:4.25

According to the CompuSyn program database, combinational therapy results at all the applied points show the synergistic feature (Figure 6.3) which is also consistent with the theoretical data produced by the software (Table 6.4). Synergism is determined according to the value called combinational index (CI). If CI value is smaller than 1, results are accepted to show synergistic effect, if it is equal to 1 showing additive effect and if it is bigger than one showing antagonistic effect.



**Figure 6.3:** Combinational Index Graph for Digoxin and Irinotecan Combination Therapy.

Another factor that determines the effectiveness and usefulness of combination therapy is called dose reduction index (DRI). The dose reduction index (DRI) is calculated using the Calcsyn software as well. DRI is used to estimate the IC50 concentration of each drug against the indicated cell lines. DRI provides valuable information to translate basic research to clinics. It (DRI) basically estimates the extent to which the dose of one or more drugs in the combination can be reduced to achieve the similar effects, which would be in comparison to those achieved with single agents.

The software has estimated DRI values for Irinotecan and Digoxin. The results are presented in Table 6.6. The results showed that 55% of the cell death could be achieved if the Irinotecan is used at 94.99  $\mu\text{M}$  in combination with 68.8  $\mu\text{M}$  Digoxin. At these combination ratios, it is possible to reduce Irinotecan's concentration 1.5 times as compared to Irinotecan alone treatment (Table 6.5). This is very promising outcome of this study since the dose reduction of highly toxic drug for cancer therapy would be great advancement in the area. However, if one desires to achieve higher cell death (>55%), extremely high concentrations of Irinotecan has to be used, which can not be translated to clinics (Table 6.5).

**Table 6.4** Theoretical and experimental comparison for combinational affect of two drugs when used in 1:4.25 ratio

THEORETICAL				EXPERIMENTAL		
Doses	CI Values	Fa	Affect	Doses	CI Values	Affect
0.20598	0.19570	0.05	SYNERGISM	76.6572	0.86559	SYNERGISM
0.60034	0.19293	0.1	SYNERGISM	102.0	0.16498	SYNERGISM
1.16419	0.19251	0.15	SYNERGISM	153.005	0.22477	SYNERGISM
1.91680	0.19304	0.2	SYNERGISM	204.007	0.12335	SYNERGISM
2.89361	0.19414	0.25	SYNERGISM	408.014	0.26808	SYNERGISM
4.14658	0.19568	0.3	SYNERGISM	816.0	0.51891	SYNERGISM
5.74919	0.19761	0.35	SYNERGISM	1224.04	0.21545	SYNERGISM
7.80536	0.19994	0.4	SYNERGISM	1632.0	0.66654	SYNERGISM
10.4646	0.20271	0.45	SYNERGISM	2040.0	0.64890	SYNERGISM

13.9471	0.20599	0.5	SYNERGISM			
18.5887	0.20990	0.55	SYNERGISM			
24.9216	0.21461	0.6	SYNERGISM			
33.8347	0.22040	0.65	SYNERGISM			
46.9115	0.22771	0.7	SYNERGISM			
67.2249	0.23726	0.75	SYNERGISM			
101.483	0.25046	0.8	SYNERGISM			
167.088	0.27025	0.85	SYNERGISM			
324.022	0.30449	0.9	SYNERGISM			
944.374	0.38570	0.95	SYNERGISM			
2021.60	0.47863	0.97	SYNERGISM			

Fa: Fraction Affected, CI: Combination Index

**Table 6.5** Dose Reduction Index Values of Digoxin and Irinotecan in Combination Therapy.

Fa	Dose Digoxin	Dose Irinotecan	DRI Digoxin	DRI Irinotecan
0.55	68.8374	94.9947	4.7123	1.53217
0.85	256.762	926.736	13.1654	11.2336
0.86	275.172	1044.71	9.40591	8.44208
0.93	533.471	3284.59	13.6763	19.9066
0.925	500.481	2941.10	6.41526	8.91244
0.927	513.176	3071.39	3.28910	4.65378
0.977	1446.47	18453.1	6.18038	18.6396
0.95	725.181	5587.28	2.32396	4.23293
0.96	886.169	7904.28	2.27189	4.79064

Fa: Fraction Affected, DRI: Dose Reduction Index.

## 7. DISCUSSION

Recently, combination therapy has been taking attention to achieve more advanced treatment for deadly disease, cancer. Several studies, some of which are summarized here, were conducted by several other groups utilizing various drugs. While in some cases the drugs chosen for the studies are two different chemotherapy agents, some studies explored combination of one chemotherapy agent with non-anti-cancer agent.

For instance, Gou and co-workers has examined the efficacy of combination therapy composed of docetaxel, flavopiridol, and 5-fluorouracil (5-FU) to assess sequential combination therapy in modulating chemosensitivity (82). They have concluded that combination therapy not only slows down tumor cell development but also induces apoptosis of HCT116 cells. In addition, it was found that sequential combination therapy was more effective than other combination therapies against HCT116 cells.

In another study, cholesterol lowering drug Statin and chemotherapy agent Irinotecan are used together to evaluate their possible synergism towards HT-29 colon cancer cells with or without Irinotecan resistance.(83). Their results showed that the combination of Statin with Irinotecan was effective to overcome Irinotecan resistance in colon cancer cells when they applied concurrently. By employing an anti-cancer agent and a non-anti-cancer drug in combination to treat colon cancer, they have proved successfulness and promise of combination therapy in the treatment of the cancer (83).

A similar study towards HCT116 was published in 2015. The authors have explored effectiveness of a combination therapy composed of Cetuximab with cytotoxic drug Cisplatin on HCT116 cells. This study showed that the combination of EGFR targeting antibody Cetuximab and Cisplatin had impact on cell growth and induction of cell apoptosis in the selected cancer cells (84). In addition to that, the results showed that the combination therapy with Cisplatin considerably improved the inhibitory impact of



Cetuximab through signaling pathway activation as well as transcriptional factors and proinflammatory genes. Furthermore, benefits of combination therapy was significantly enhanced by the combination treatment of Cetuximab and Cisplatin when matched up to that of cells treated with cetuximab or cisplatin alone (84).

In another study on colon cancer HCT-116 cells, the combination therapy based on natural flavonoids Quercetin and Kaempferol was conducted in 2013 (85). Preliminary data based on IC50 values for each drug showed that the Quercetin was more potent than Kaempferol. Nevertheless, the cytotoxic efficacy enhanced considerably when these drugs used in combination. It is remarkable to observe that Quercetin and Kaempferol interacted in a synergistic manner on HCT-116 cells (85,86). The authors noted that they achieved the most favorable results when two fold Quercetin and one fold Kaempferol were used in combination. (87) That study recommended that the quercetin and kaempferol combination effectively could target the cellular machinery vital to the cell development of this aggressive, microsatellite-unstable, and growth hormone-autonomous human colon cancer line (85,86, 88).

Besides cytotoxic agents, as in the case of this Master thesis, cardiac glycosides' anti-cancer properties have also been explored. Cardiac glycosides have also been found to have a number of other effects, including altering serum androgen levels and inhibiting tumor growth and development (89,90) Recently, Digoxin has been proposed as both a potential therapeutic in cancer therapy as well as a cancer prevention agent (91). A study showed that digoxin was able to inhibit breast cancer proliferation and activate extracellular signal-regulated kinase (ERK1/2) at concentrations lower than 100 nM in breast cancer cell lines (92). Longer duration of using CGs showed a protective role of digoxin against prostate cancer risk. A pre-clinical study showed that digoxin increases intracellular  $Ca^{+2}$  causing changes leading to prostate cancer cells apoptosis. The mechanism by which CGs can alter the proliferation of prostate cancer cells remains

unclear. This study demonstrated that Digoxin was able to inhibit tumor cell migration and invasion (93).

There are several other studies regarding anti-cancer effect of antiarrhythmic drug Digoxin. For instance one study has reported promising results of Digoxin's inhibitory effect on prostate cancer cell line (94). In the same study, Digoxin has been reported to have apoptosis-inducing and cytotoxic effects on prostate cancer cells. In addition, Digoxin has been shown to inhibit primary tumor growth and the metastasis of cancer cells from breast to lung in an orthotopic model in which human breast cancer cells were implanted into SCID mice (95).

Another study revealed the ability of Digoxin to inhibit lung cancer proliferation, migration, and invasion in vitro (96) In addition, it was found that Digoxin inhibited the formation of A549 cell colonies in a dose-dependent manner (10, 25, 50 and 100 nM) in short period of time. The authors studied the mechanism of inhibition as well concluded that Digoxin greatly suppresses cancer progression by inhibiting the activity of Src oncogene (97).

One of the most sensitive and the most exciting studies on Digoxin was the study that is intended to assess the effect of Digoxin on the growth of human SH-SY5Y and SK-N-AS neuroblastoma cell lines (98). The  $IC_{50}$  values for each cell line were as low as 34 and 22 ng/mL, respectively. The authors also reported that Digoxin significantly reduced the growth of human SH-SY5Y neuroblastoma cells xenotransplanted in immunodeficient mice. The authors concluded that Digoxin might be a specific neuroblastoma growth inhibitor (99).

Irinotecan, the second drug that was chosen for this master thesis, is currently approved for the treatment of metastatic CRC. It is a first-line therapeutic along with leucovorin (LV) and 5-FU. It is also a recommended agent for recurrent and uncontrollable disease that has progressed despite treatment with 5-FU. The combination of Irinotecan/5-FU/LV is superior to 5-FU/LV alone as first-line therapy for patients with metastatic colorectal cancer, offering consistently improved tumor control and

prolonged survival. Irinotecan-based combination therapy sets a new survival standard for the treatment of this life-threatening disease (100).

Although cytotoxic drugs are widely used in clinics for tumor treatment, severe toxicity restricts their therapeutic efficacy. Therefore, studies are carried out to reduce side effects of drugs. For instance, a study was conducted in 2014 to investigate Selenium nanoparticles, Nano Se, as chemotherapy preventive agent to protect cells against toxicities Irinotecan (101). It is shown that Nano Se synergistically enhanced the anti-tumor effect of Irinotecan in vitro and in vivo. The combination of Nano Se and irinotecan showed increased cytotoxic effect against HCT-8 tumor cells believed to be through p53 mediated apoptosis. The combination of Nano Se and Irinotecan dramatically inhibited tumor growth and significantly induced apoptosis of tumor cells in HCT-8 cells xenografted tumor as well (101).

As literature search revealed, there are several studies for combination therapy of cancer. Mostly, these studies include two different cytotoxic agent or Irinotecan or Digoxin in combination with other drugs. To the best of our knowledge, there is only one study published in 2009 in which Irinotecan and Digoxin have been used in combination towards HCT116 cell line (102). While our findings are in agreement to their results, our drug concentrations are quite different than theirs. For instance, they conducted the study using IC70 values of each drug while we carried the study by employing IC50 values of both of the drugs at certain ratio. Therefore, this study is unique in terms of used drug combinations and drug concentrations.

In this study, our major goal was to determine the cytotoxic effects of Digoxin and Irinotecan in the form of combination therapy. At first, the cytotoxic effect of Digoxin has been examined on HCT 116 colon cancer cell line by employing various concentrations of this medicine. In addition, cytotoxic activity of Irinotecan has also been explored on HCT 116 colon cancer cell line at wide range of concentrations.

The results indicated that Digoxin effectively slows down the growth of HCT-116 colon cancer cells in a dose-dependent manner. In addition to that, our results showed that Digoxin is not only effective on cell viability and proliferation, but also has the synergistic antitumor effect with Irinotecan towards HCT-116 cells. To be more specific, at 78  $\mu\text{M}$  Digoxin and 330  $\mu\text{M}$  Irinotecan, it was seen that 50% of the cells were dead when these two drugs were applied individually. However, when they were applied at the same time, at 1:4.23 (Digoxin: Irinotecan) ratio, 13.9  $\mu\text{M}$  of total dose of two drugs is required to achieve 50% cell death. Moreover, at all concentration points for these two drugs, synergism was determined. This means that these two drugs can be used to generate more effective treatment for colorectal cancer as well as for other cancer types in near future.

However, one major drawback of our result is that Irinotecan, chemotherapy agent, is required to be used at high concentration to achieve more than 55% cell death. As seen in Table 6.6, in all conditions except 55% cell death, DRI values are in favor for Digoxin instead of Irinotecan. Since Irinotecan has serious side effects, new therapies such as sequence dependent, time dependent and concentration dependent should be designed to overcome this problem.

All these studies as well as our study show that Digoxin and Irinotecan based combination therapies need to be improved to reduce Irinotecan dose since it is toxic to the healthy cells as well. Synergism between these two drugs can be used to effectively reduce Irinotecan dose in order to reduce side effects and improve patients' life quality. Sequence dependent studies, as well as mechanistic studies should be performed.

It is also essential to use animal models to study the combination effect of these drugs to assess animal survival as an endpoint for the experiments. In our opinion, animals with colorectal cancer should be treated with several different concentrations of the combination of these two drugs to conclude the effectiveness of the study. In addition, toxicity studies for the several other organs such as kidney, lung, pancreas should be carried out before making a final decision for the combination therapy results.

In the combination of these drugs, Digoxin and Irinotecan could be integrated to drug delivery systems such as liposome, nanoparticles, organic nanoparticles to increase the concentration of number of drugs per cell. Moreover, it would be near ideal if these drug delivery system have targeting agents such as peptide, antibody which would carry the whole system directly to the cancer cell. By doing so, it would be possible to greatly shelter neighboring healthy cells' from the harmful effect of drugs. The use of the drug delivery systems were effectively utilized so as to get better entire therapeutic index of anticancer drugs by raising their antitumor activity or by decreasing their toxicity profile. Effectively clinical appliance of this rationally-designed method to cancer therapy relays on the improvement of drug quality, with precise features, which delivers the drug combination in vitro so that the efficient drug ratio is sustained after systemic management and is eventually exposed to cancer. By doing do, the incapability to manage drug ratios in systemic circulation, and largely in tumor tissue, might partially clarify the short outcome in clinical efficiency observed for conventional free drug combinations.

As conclusion, colon cancer is one of the major drivers of mortality throughout the world. Thus, looking for successful chemotherapeutic treatments or treatment combinations is still a great need. As seen in several examples, combination therapy significantly contributes to and extends the field of anti-cancer therapy. Drug combination studies on tumor cell lines permit to design variety of treatment options of future chemotherapy protocols. The interpretation of precise drug ratios, formerly chosen in vitro, to the clinical setting is complicated because of the autonomous pharmacokinetics and biodistribution of individual treatments intravenously managed as aqueous-based free drug cocktail. The referred uncoordinated pharmacokinetics lead to exposure of tumor cells to drug concentrations below therapeutic threshold degree or to antagonistic drug ratios with concomitant loss of therapeutic activity

To establish chemotherapeutic treatment combinations, it must be founded on a balanced choice of the medicines to be combined and on a systematic as well as quantitative monitoring of the ratio-dependent anti proliferative effects against HCT-116

colon cancer cell line. Drug combination studies on colon cancer cell line utilizing a quantitative approach to assess the character of drug relations, permit a further rational design of future chemotherapy protocols.

To sum up, the present study displays that the Digoxin combined with Irinotecan in human colon cancer cells has synergistic effects on cell death. Thus, the combination of Digoxin and Irinotecan might be a helpful medication for colon cancer, with a higher effectiveness and fewer side effects than other treatments. All these findings in our study might create synergistic impacts on cancer medications, which is promising for to improve therapeutic efficiency of these two agents.

## 8. References

1. Gearhart S & Ahuja N. Early diagnosis and treatment of cancer series: Colorectal cancer. Elsevier Inc, Philadelphia.2011.
2. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. Global cancer statistics,. CA Cancer J. Clin. 55, 74-108.2005.
3. Lai SM, Zhang KB, Uhler RJ, Harrison JN, Clutter GG, Williams MA. Geographic variation in the incidence of colorectal cancer in the United States, 1998-2001. Cancer; 107(5 Suppl): 1172-1180, 2006.
4. Haggard F.A. and Boushey R.P.Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clinics in colon and rectal surgery 22(4), 191.2009.
5. Thompson M., Perera R., Senapati A. and Dodds S.Predictive value of common symptom combinations in diagnosing colorectal cancer. British journal of surgery94 (10), 1260-1265, 2007.
6. Lau PC, Sung JJ. Flat adenoma in colon: two decades of debate. Journal of digestive diseases; 11(4): 201-207, 2010.
7. Schwartzmann G, Winograd B, Pinedo HM. The main steps in the development of anticancer agents. Radiother Oncol; 12: 301–313. 1988
8. Shiratori, O. Growth inhibitory effects of cardiac glycosides and aglycones on neoplastic cells: In vitro and in vivo studies. Gann 58, 521–528 (1967).
9. Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Sukkurwala A, Q, Michaud M, Galluzzi L, Zitvogel L, and Kroemer G. Anticancer activity of cardiac glycosides At the frontier between cell-autonomous and immunological effects. J. Oncolimmunology, 1,9, 1640-1642. 2012.

10. Molecular Targets and Cancer Therapeutics Poster Session C Sunday, AACR-NCI-EORTC International conference, John B. Hynes Veterans Memorial Convention Center, Boston. November 8, 2015.
11. Haux J. Digitoxin is a potential anticancer agent for several types of cancer. *Medical Hypotheses*; 53 543-548.1999.
12. Pommier Y, Tanizawa A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. In: Liu LF, ed. *Advances in Pharmacology*. New York: Academic Press; 29B:73-92, 1994.
13. Goldberg, R.M., Loprinzi, C.L. Cancer anorexia/cachexia. *Cancer Treatment and Research*, 100, 31-41, 1999.
14. Hanahan D, Weinberg R, Hallmarks of cancer: the next generation. *Cell* 144:646-674, 2011
15. Jaramillo M, Tibiche C Cancer Genomics to Cancer Biology. In *Cancer Systems Biology*, Wang E (ed), 12, pp 215-232. London: CRC Press, 2010.
16. Hillen, H. Enderling, and P. Hahnfeldt. The tumor growth paradox and immune system-mediated selection for cancer stem cells. *Bulletin of Mathematical Biology*, 75,161184, 2013.
17. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature*; 444:633–637.2006.
18. MN. Chatterjea, Rana Shinde. *Medical Biochemistry*, Eighth Edition, 792-793, 2012.
19. Michor, F., Iwasa, Y., & Nowak, M. A. Dynamics of cancer progression. *Nat Rev Can* 4, 197–205.2004.



20. Sieber, O. M., Heinemann, K., & Tomlinson, I. P. Genomic instability - the engine of tumorigenesis?. *Nat Rev Can* 3, 701–708.2003.
21. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin*; 62: 10 – 29, 2012.
22. Bjerkvig R, Johansson M, Miletic H, et al. Cancer stem cells and angiogenesis. *Semin Cancer Biol*; 19:279–284.2009.
23. O.Abdel-Wahab, A. Dey, The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics, *Leukemia* 27, 10–15, 2013.
24. Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten, R.E., Wei, R., Fleming, M.D., Schreiber, S.L., and Cantley, L.C.. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature* 452:230-233.2008.
25. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science*; 324: 1029 – 33, 2009.
26. Mayevsky A: Mitochondrial function and energy metabolism in cancer cells: Past overview and future perspectives. *Mitochondrion* 2009.
27. DeBerardinis, R. J. J. J. Lum, G. Hatzivassiliou, and C. B. Thompson.. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. *Cell Metabolism* 7 (1) (Jan): 11-20, 2008.
28. Yuneva M: Finding an “Achilles’ heel” of cancer: the role of glucose and glutamine metabolism in the survival of transformed cells. *Cell Cycle*, 7:2083-2089.2008.
29. Buzzai, M. D. E. Bauer, R. G. Jones, R. J. Deberardinis, G. Hatzivassiliou, R. L. Elstrom, and C. B. Thompson.. The glucose dependence of akt-transformed cells can be

reversed by pharmacologic activation of fatty acid beta-oxidation. *Oncogene* 24 (26) (Jun 16): 4165-73, 2005.

30. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? *Nat Rev Cancer*; 4:891–899.2004.

31. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. *PNAS*; 107(19):8788–93, 2012.

32. Burkitt, D. P. Epidemiology of cancer of the colon and rectum. *Cancer*, 28: 3-13, 1971.

33. Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, Sancho FJ, Peinado MA & Capella G, p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. *J Clin Oncol* 5, 1375-1381, 1999, 1574-1594, 2003.

34. Grady, W.M. Genetic testing for high risk colon cancer patients. *Gastroenterology* 124, 1574-1594, 2003.

35. Tornell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L & Isaksson O, High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. *J Steroid Biochem Mol Biol* 1-3:237-242.1992.

36. Gelboin H.V. Genetic and environmental factors in experimental and human cancer: proceedings of the 10th international symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, 1979: Japan Scientific Societies Press.1980.

37. Calton BA, Lacey JV, Schatzkin A et al. Physical activity and the risk of colon cancer among women: A prospective cohort study (United States). *Int. J. Cancer*; 119:385–391.2006.
38. Nock NL, Thompson CL, Tucker TC, et al. Associations between Obesity and Changes in Adult BMI over Time and Colon Cancer Risk. *Obesity*; 16: 1099-1104, 2008.
39. DePinho R.A. The age of cancer. *Nature*408 (6809), 248-254.2000.
40. Wirfält, E., Midthune, D., Reedy, J., Mitrou, P., Flood, A., Subar, A.F. Leitzmann, M., Mouw, T., Hollenbeck, A.R., Schatzkin, A., and Kipnis, V. Associations between food patterns defined by cluster analysis and colorectal cancer incidence in the NIH-AARP diet and health study. *Eur. J. Clin. Nutr.* 63, 707-717.2009.
41. Zisman A.L., Nickolov A., Brand R.E., Gorchow A. and Roy H.K. Associations between the age at diagnosis and location of colorectal cancer and the use of alcohol and tobacco: implications for screening. *Archives of internal medicine*166 (6), 629-634.2006.
42. Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. *Ann Oncol*; 22(9): 1958-72. 2011.
43. Debridge A, Valente L, Strasser A. The Role of the Apoptotic Machinery in Tumor Suppression. *Cold Spring Harb Perspect Biol*4: 1-14, 2012.
44. Fadeel, B. and Orrenius, S., Apoptosis: a basic biological phenomenon with wideranging implications in human disease. *Journal of Internal Medicine*,. 258: p. 479-517.2005.

45. Broker, L.E., et al., Cell death independent of caspases: a review. *Clinical Cancer Research*, . 11: p. 3155-3162, 2005.
46. Jin, Z. and El-Deiry, W.S., Overview of cell death signaling pathways. *Cancer Biology and Therapy*. 4: p. 139-163.2005.
47. Fesik, S.W. Promoting apoptosis as a strategy for cancer drug discovery. *Nature Reviews. Cancer*,. 5: p. 876-885.2005.
48. Kerr, J.F., et al., Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *British journal of Cancer*. 26: p. 239-257.1972.
49. C. P. Karger. Biological models in treatment planning. *Medical Radiology*, pages 221235, 2006.
50. Abulafi A. and Williams N. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. *British journal of surgery*81(1), 7-19.1994.
51. Folger, O., L. Jerby, C. Frezza, E. Gottlieb, E. Ruppin, and T. Shlomi.. Predicting selective drug targets in cancer through metabolic networks. *Molecular Systems Biology* 7 (Aug 23): 527.2011.
52. Arkhipov A. Supportive document for the preparation of the core data sheet for CAMPTOSAR (irinotecan) regarding postmarketing surveillance. Pharmacia & Upjohn, Corporate Pharmacovigilance, US, 1999.
53. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and Irinotecan. *Cancer Treat Rev*;20:73-96.1994
54. Yves P. Eukaryotic DNA topoisomerase I: genome gatekeeperand its intruders, camptothecins. *Semin Oncol*;23(suppl3):3-10.1996.

55. Douillard, JY, Cunningham, D, Roth, AD et al, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet.* ; 355:1041–1047. 2000.
56. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. *N Engl J Med*; 343:905–914. 2000.
57. Pommier Y, Tanizawa A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. In: Liu LF, ed. *Advances in Pharmacology*. New York: Academic Press; 29B:73-92, 1994.
58. Menger L, Vacchelli E, Kepp O, et al. Trial watch - Cardiac glycosides and cancer therapy. *Oncoimmunology*; 2:e23082, 2013.
59. Mijatovic T, Ingrassia L, Facchini V, Kiss R. Na<sup>+</sup>/K<sup>+</sup>-ATPase alpha subunits as new targets in anticancer therapy. *Expert Opinion on Therapeutic Targets*; 12 1403-1417, 2008.
60. Biggar RJ. Molecular pathways: digoxin use and estrogen-sensitive cancers - risks and possible therapeutic implications. *Clin Cancer Res.*; 18, 2133–2137. 2012.
61. Li Z, Zhang Z, Xie JX, Li X, Tian J, Cai T, et al. Na/K-ATPase mimetic pNaKtide peptide inhibits the growth of human cancer cells. *J Biol Chem*; 286:32394–403.2011.
62. Kumar S., Cardiac Glycosides as Anticancer Agent. *International Journal of Research in Pharmaceutical and Biomedical Sciences*, India.
63. Yang P, Menter DG, Cartwright C, Chan D, Dixon S, Suraokar M, Mendoza G, Llansa

N, Newman RA. Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. *Molecular Cancer Therapeutic*;8 2319-2328,2009.

64. López-Lázaro M. Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. *PubMed*, 11(8):1043-53, 2007.

65. Felth J, Rickardson L, Rosen J, Wickstrom M, Frykn € €as M, Lindskog M, et al. Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs. *J Nat Prod*; 72: 1969–74, 2009.

66. Aperia A. New roles for an old enzyme: Na,K-ATPase emerges as an interesting drug target. *Journal of Internal Medicine*; 261 44-52, 2007.

67. Jaanus SD, Bartlett JD, Hiatt, JA. Ocular effects of systemic drugs. In: Bartlett JD and Jaanus SD, eds. *Clinical Ocular Pharmacology*, 3rd ed. Boston: Butterworth-Heinemann,;957- 1006,1995.

68. Luchi RJ, Gruber JW. Unusually large digitalis requirements: a study of altered digoxin metabolism. *Am J Med*; 45: 322-8, 1968.

69. Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. *Nature Reviews. Drug discovery*; 7 926-95, 2008.

70. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer Res.*; 70: 440-446.2010.

71. Mayer L.D. & Janoff A.S. Optimizing combination chemotherapy by controlling drug ratios. *Mol Interv*, vol.7, No.4, pp. 216-223, ISSN 1534-0384, September 2007.

72. Seymour, MT, Maughan, TS, Ledermann, JA et al, Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS):a randomised controlled trial. *Lancet.* ;370:143–152. 2007.

73. Saif, M, Kim, R, Chu, E. Cytotoxic chemotherapy for metastatic colorectal cancer. in: LB Saltz (Ed.)Colorectal Cancer: Evidence-Based Chemotherapy Strategies. Humana Press, Totowa, NJ; :69–70. 2007.
74. Koopman, M, Antonini, NF, Douma, J et al, Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. *Lancet*. 2007;370:135–142. 2007.
75. Wai M Liu, St George's, University of London, London, UK Katherine A Scott, St George's, University of London, London, UK Angus G Dalglish, St George's, University of London, London, UK Combination Therapy in Cancer. 2016.
76. Menard C Martin F Apetoh L , et al. . Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity *Cancer Immunol Immunother*, vol. 57 (1579-1587).2008.
77. Christopher, K. Mathews.DNA Synthesis as a Therapeutic Target: The First 65 Years, 26(6): 2231–2237.; 2012.
78. BayatMokhtari R., Homayouni TS., Baluch N., Morgatskaya E., Kumar S., Das B., Yeger H. Combination therapy in combating cancer. *Oncotarget*. 6;8(23):38022-38043. 2017.
79. Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. *J Clin Oncol*. (31):1592–605. 2013
80. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. *J Natl Cancer Inst Monogr*. (30):135–42. 2001.

81. Blagosklonny MV. "Targeting the absence" and therapeutic engineering for cancer therapy. *Cell Cycle*. (7):1307–12. 2008.
82. Guo J., Zhou AW, Fu YC, Verma N. U., Tripathy D., Pfenkel E. and Becerra C. R. Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. *Acta Pharmacologica Sinica*, 1375–138. 2006.
83. Hyun J. J., Hong E.M., Jang J., Choi J. E., Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance, *J. Gastroenterol Res Pract*. 2016; 2016: 7891374. 2016.
84. Son D. J. , Hong J. E., Ban J. O. , Park J. H. , Lee H. L. , Gu S. M., Hwang J. Y., Jung M. H., Lee D. W. , Han SB., and Hong J. T. Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway. *BioMed Research International*, Vo. 2015 (2015), 13 pages. 2015.
85. Jaramillo-Carmona S., S., Abia R., Rodriguez-Arcos R. Jimenez A., Guillen R. and Francisco J.G. Combination of Quercetin and Kaempferol enhances in vitro Cytotoxicity on Human Colon Cancer (HCT-116) Cells, *Rec. Nat. Prod.* 8.3, 262-271. 2014.
86. R. A. Awwad, N. Sergina, H. Yang, B. Ziober, J. K. Willson, E. Zborowska, L. E. Humphrey, R. Fan, T. C. Ko, M. G. Brattain, et al. The role of transforming growth factor alpha in determining growth factor independence, *Cancer Res.* 63, 4731–4738, 2003.
87. M. L. Ackland, S. van de Waarsenburg and R. Jones. Synergistic antiproliferative action of the flavonoids quercetin and kaempferol in cultured human cancer cell lines, *In Vivo* 19, 69–76, 2005.



88. M. L. Ackland, S. van de Waarsenburg and R. Jones Synergistic antiproliferative action of the flavonoids quercetin and kaempferol in cultured human cancer cell lines, *In Vivo* 19, 69–76. (2005).
89. Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. *Mol Interv*; 8:36–49. 2008.
90. Stoffer SS, Hynes KM, Jiang NS, Ryan RJ. Digoxin and abnormal serum hormone levels. *Jama*. 225(13):1643–1644.1973.
91. Lin H, Juang JL, Wang PS. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. *J Biol Chem*. 279 (28):29302–29307..2004.
92. Lin H, Juang JL, Wang PS. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. *J Biol Chem*. 279 (28):29302–29307,2004.
93. Osman MH, Farrag E, Selim M, Osman MS, Hasanine A, Selim A. Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies. *journal. pone.0178611, PLoS ONE* 12(6): 2017.
94. Platz EA, Yegnasubramanian S, Liu JO, et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. *Cancer Discov*; 1:68–77,2011.
95. Kaapu KJ, Ahti J, Tammela TL, Auvinen A., Murtola TJ. Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study. *Int J Cancer*. 1; 137(5):1187-95. 2015.
96. Lin SY, Chang HH, Lai YH, Lin CH, Chen MH, Chang GC, Tsai MF, Chen JJ. Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer. 8; 10(5), *journal. pone.0123305. eCollection*. 2015.

97. Lin SY, Chang HH, Lai YH, Lin CH, Chen MH, Chang GC, Tsai MF, Chen JJ. Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer. 8; 10(5), journal. pone.0123305. eCollection. 2015.
98. José M., Calderón-Montaño, Estefanía BM, Manuel L. O., Dolores MN., Irene GD., and Miguel LL. Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides. *BioMed Research International*, Volume 2014 (2014).
99. James J. V., Annick D., David A. R., and Henry S. F. Experience with irinotecan for the treatment of malignant glioma. *J. Neuro Oncol*; 11(1): 80–91. 2015.
100. Leonard B. S., Jean-Y. D., Nicoletta P., May A., Gabriela G., Lucile A., Gary L. E. Irinotecan Plus Fluorouracil/Leucovorin for Metastatic Colorectal Cancer: A New Survival Standard. *J. The oncologist*, vol. 6 no. 1 81-91, 2001.
101. Gao F, Yuan Q, Gao L, Cai P, Zhu H, Liu R, Wang Y, Wei Y, Huang G, Liang J, Gao X. Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles. *J. biomaterials*, 35(31):8854-66. 2014.
102. Felth J, Rickardson L, Rosén J, Wickström M, Fryknäs M, Lindskog M, Bohlin L, Gullbo J. Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs. *J Nat Prod*. 2009 Nov;72(11):1969-74. 2009.

## 9.CURRICULUM VITAE

### Personal Information

Name	Kalif Mohamed	Last Name	Mohamud
Date of Birth	5 04 1981		
Nationality	Somali	E-mail	<a href="mailto:kalifsome@gmail.com">kalifsome@gmail.com</a>

### Education Level

	Name of the Institute	Year of Graduation
MSc	Istanbul Medipol University	2017
Undergraduate	Mogadishu University	2010
High School	Ahmed Gurey School	2006

### Work Experience

Title	Name of Organization	Duration (Year-Year)
1.Teacher of Biology and Chemistry	Al-iman School	2010-2015
2.Administration Member	Al-iman School	2013-2015
3.Lecturer of G. chemistry	Zamzam University	2016-2017

Foreign Languages	Reading	Speaking	Writing
Arabic	Very good,	Very good,	Very good,
English	Very good,	Very good,	Very good,

\* Very good, good, average, below average

### Computer Skills

Software	Skill
Microsoft Word	Good
Microsoft Exel	Good
Microsoft Power point	Good

\*Very good, good, average, below average

Publications/Abstracts/Certificates/Awards/Other

I have high school and first degree certificate

Ulusal Moleküler Tip Sempozyumu, Haziran, 1-3, 2016, İstanbul, *Poster Presentation* "Digoxin'in HCT 116 Hücre Hatlarındaki Etkisi: Digoxin hem Kronik Kalp Yetmezliği hem de Kolon Kanserinin Tedavisi Olabilir mi? Vildan Obeidin, A. Vildan, Mohamud, Kalif Mohamed ; Erdem, Sibel S.